Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | PKM | P14618 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56881 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL4844382 | 0.85 | ALDH1A1 (0.70) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL6788102 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL6793640 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL56882 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL6792690 | 0.81 | ALDH1A1 (0.65) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL6191755 | 0.80 | PGK1 (0.54) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL27583371 | 0.79 | ALDH1A1 (0.62) | ALDH1A1KMT2APKMMEN1MAPT | |
| Hydrochloric Acid SCHEMBL4849352 | 0.79 | RAB9A (0.54) | ALDH1A1KMT2APKMMEN1MAPT | |
| SCHEMBL6017266 | 0.78 | ALDH1A1 (0.59) | ALDH1A1KMT2APKMMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429278-B2 | N-alkyleheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'ORÉAL (FR) | 2008-09-30 | — | — | US | disclosed |
| US-7429278-B2 | N-alkyleheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'ORÉAL (FR) | 2008-09-30 | — | — | US | disclosed |
| US-7429278-B2 | N-alkyleheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'ORÉAL (FR) | 2008-09-30 | — | — | US | disclosed |
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
| US-20060005320-A1 | N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1589012-A2 | N-alkylheteroaryl secondary para-phenyldiamine, dyeing composition containing the same, process for making it and uses thereof | L'OREAL (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | KRT18, CDC73, PRKDC | ALDH1A1 575/4885KMT2A 722/4885PKM 38/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | ALDH1A1 1427/4885KMT2A 2457/4885PKM 3447/4885 |
| US-20060005320-A1 | N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | KRT18, CDC73, PRKDC | ALDH1A1 575/4885KMT2A 722/4885PKM 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.